Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02706691 · ClinicalTrials.gov registry record · Phase 2
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02706691: Clinical Trial Phase 2 study, sponsored by University of Chicago.
NCT02706691 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02706691, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has returned after a period of improvement. BGJ398 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG BGJ398
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2019-02-11 |
| Phase | Phase 2 |
Why NCT02706691 stopped before completion
NCT02706691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which BGJ398 is the first listed.
NCT02706691 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02706691 about?
NCT02706691 is a clinical study titled "BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer". This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has returned after a period of improvement. BGJ398 may stop the growth of tum...
What is the current status of trial NCT02706691?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2018-06-01. Estimated completion is 2019-02-11.
What interventions are being tested in trial NCT02706691?
The interventions under investigation include: BGJ398 (DRUG).
Who is sponsoring clinical trial NCT02706691?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02706691's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI